Experimental observations on prophylactic and therapeutic vaccination against foot-rot in sheep

Extract

I have taken as my subject for this address the topic, “Change”, and will deal with two aspects of change, one the challenge of change due to new knowledge and techniques and second the change we must make in our attitude to other agricultural disciplines and ancillary veterinary personnel.     

A field trial to assess the therapeutic and prophylactic effect of a foot rot vaccine in sheep

An 18-week field trial was conducted on a sheep ranch to evaluate the therapeutic and prophylactic effect of a commercial foot rot vaccine. Two hundred sheep were included in the study, 100 with detectable foot rot lesions and 100 without. Approximately 50 sheep from each group were selected randomly and vaccinated twice against foot rot at a 6-week interval in the late spring 1984; the remaining sheep acted as nonvaccinated controls. Therapeutic effect of the vaccine was demonstrated by a cure rate of 53% in vaccinated, foot rot-affected sheep vs a cure rate of 19% in nonvaccinated, foot rot-affected sheep. Prophylactic effect of the vaccine was demonstrated by a foot rot prevalence at the end of the 18-week period of 9% for vaccinated sheep vs 53% for nonvaccinated sheep. Associations of foot rot lesions and vaccination with body condition were found to be significant, as was the association between foot rot lesions and mortality.     

A field trial with a multicomponent inactivated respiratory viral vaccine.

An inactivated virus vaccine containing strains of parainfluenza type 3 (PI3), bovine adenovirus type 3, reovirus type 1, bovine virus diarrhoea (BVD) and infectious bovine rhinotracheitis (IBR) viruses was tested in a group of 58 calves reared in a semi-intensive management system. Following vaccination, 1/30, 14/30 and 17/30, showed significant rises in antibody titre to reovirus type 1, adenovirus type 3 and IBR respectively. None of the animals showed significant serological response to PI 3 and BVD. In the control group, 2/28, 1/28, 6/28 and 3/28 developed antibody responses to reovirus type 1, BVD, adenovirus type 3 and IBR respectively. Microbiological examination revealed the presence of a wide variety of commensal bacteria and Mycoplasma bovirhinis in both groups. Analysis of the records of clinical examinations indicated that the respiratory tract infections occurred among the calves at between 50 and 80 days after arrival at the farm, and that there was no significant difference between the test and the control groups. A number of animals had maternal antibodies to the various components of the vaccine present before the trial commenced and these antibodies appeared to interfere with the subsequent serological response to the antigen challenge. The vaccination schedule recommended by the manufacturer does not entirely circumvent this problem.     

Randomized blind trial of a commercial FeLV vaccine

A randomized blind trial of a commercial FeLV vaccine was conducted to evaluate its performance in cats under conditions of long-term natural exposure. Seventy-nine nonviremic, seronegative cats were randomized into 2 groups. Cats were given 3 doses of either FeLV vaccine or placebo (killed rabies virus vaccine) sc at weeks 0, 3, and 9 of the trial. Six weeks later, 44 known-viremic cats were added to the colony. Cats were housed in a single large room and food dishes and litter pans were used in common. Blood samples were collected at 4, 8, and 12 months after the addition of the viremic cats and were assayed for viremia by use of ELISA. Twelve-month samples were also assayed independently by use of indirect fluorescent antibody testing. Investigators conducted assays on coded samples without knowledge of the cat's vaccination status; neither the investigators nor colony personnel knew which cats had been given the FeLV vaccine and which had been given the placebo until the twelfth month of exposure. After 12 months of cohabitation with infected cats, vaccinated cats had a significantly (P less than or equal to 0.02) lower incidence of persistent viremia (defined as 2 positive ELISA test results at least 8 weeks apart or 1 positive indirect fluorescent antibody test result), compared with the placebo-inoculated cats. The incidence of persistent viremia was approximately 3 times greater among the placebo-inoculated cats than among vaccinates.     

Efficacy of a piglet-specific commercial inactivated vaccine against Porcine circovirus type 2 in clinical field trials

The efficacy of a piglet-specific inactivated Porcine circovirus type 2 (PCV2) vaccine was evaluated with clinical field trials, as recommended by the Republic of Korea’s Animal, Plant & Fisheries Quarantine & Inspection Agency. Three farms were selected on the basis of their history of postweaning multisystemic wasting syndrome. On each farm 60, 1-week-old pigs were randomly allocated to 1 of 2 treatment groups: vaccination at 1 and 3 wk of age or no vaccination. The 2-dose schedule of vaccination with inactivated PCV2 vaccine improved the average daily weight gain from birth to 16 wk of age, the PCV2 load in the blood, and the frequency and severity of lymph node lesions. Inactivated PCV2 vaccine seems to be very effective in controlling PCV2 infection under field conditions.     

A field trial to evaluate a whole cell vaccine for the prevention of caseous lymphadenitis in sheep and goat flocks.

A field trial to evaluate a whole cell vaccine for the prevention of caseous lymphadenitis (CLA) in sheep and goats was performed in one goat herd and one sheep flock over a period of three years. In goats, there was a nonstatistically significant trend for fewer cases of CLA in the vaccinated animals compared to the controls. In sheep, from six months to 36 months postinitial vaccination, the proportion of vaccinated sheep that developed CLA was significantly less (p less than 0.05) than in the control sheep. The antibody titers to Corynebacterium pseudotuberculosis as detected by microagglutination assay were significantly different (p less than 0.0001) at all times except at the initial vaccination. Swellings occurred at the vaccination site at an incidence level of 29.6% in goats and 34.1% in sheep. The vaccine appeared to be efficacious in reducing the proportion of sheep that developed CLA when challenged naturally in a field situation.     

Experimental field trial with an immunostimulating complex (ISCOM) vaccine against contagious bovine pleuropneumonia

The experimental field trial with an immunostimulating complex (ISCOM) vaccine has been an occasion to explore the role of a Th1 response in the pathogenesis caused by Mycoplasma mycoides subsp. mycoides small colony (MmmSC) and in immune protection. The ISCOM complex is known to promote Th1 response. Antibodies to MmmSC were detected by indirect enzyme-linked immunosorbent assay (ELISA) in the vaccinated cattle, although the levels were lower than in a previous study. No antibodies were detected by complement fixation test (CF). After the challenge infection, vaccinated animals developed CF antibody response. They showed significantly reduced mortality compared with controls. However, gross pathological and histopathological score for vaccinated animals was as high as for the non-vaccinated, characterized by a high inflammatory reaction with histopathology dominated by interlobular pneumonia with vasculitis.     

An outbreak of Pasteurella multocida pneumonia in lambs during a field trial of a vaccine against Pasteurella haemolytica

A vaccine against pneumonic pasteurellosis was evaluated for efficacy at two dilutions in lambs transported by sea from New Zealand to Saudi Arabia. The experimental vaccine was a killed Pasteurella haemolytica serotype A1 and A2 preparation. There was no evidence of either dilution of the vaccine leading to a lower pneumonia death or lesion rate than for the control group. However, bacteriological examinations to establish the causality of the pneumonia cases showed Pasteurella multocida to be the dominant organism, while P. haemolytica types A1 and/or A2 occurred at only a very low incidence.     

Year two of follow-up evaluation of a randomized, blind field trial of a commercial feline leukemia virus vaccine.

A blind randomized field trial of a commercial FeLV vaccine was conducted. Cats on study were vaccinated with either a commercial FeLV vaccine or a placebo, then housed with FeLV-positive cats in a ratio of approximately 2 study cats to 1 infected cat (results of the first 12 months of the study have been reported). All surviving placebo-treated and FeLV-vaccinated cats were re-vaccinated 1 year after initial exposure to FeLV-infected cats. Exposure continued for an additional 12 months, and the viremia status of the cats was monitored by immunofluorescent antibody (IFA) and ELISA testing at 4-month intervals. During the second year of observation, 1 additional FeLV-vaccinated cat had positive results of 2 consecutive ELISA tests, but remained IFA negative. Classifying this cat as persistently viremic reduced the estimate of the preventable fraction, but did not alter the conclusions drawn earlier, viz, that vaccination appreciably reduces the number of cats that become persistently viremic after long-term natural exposure.     

Induction of cross-protection in mice against dolphin Erysipelothrix rhusiopathiae isolates with a swine commercial vaccine

Erysipelothrix rhusiopathiae is well known to cause disease in dolphins. This disease occurs either in an peracute way, leading to mortality even before clinical signs are observed or in a sub-acute way, characterized by rhomboidal skin lesions, that can be treated with penicillin or its derivatives. Commercial swine vaccines, containing inactivated serotype 2 strains, are currently used for vaccination but it is not known whether these vaccines induce protection against E. rhusiopathiae isolates from dolphins. In the present study, it was demonstrated in a mouse model that vaccination with a commercial swine vaccine (Eurovac Ery, Eurovet, Belgium) containing inactivated serotype 2 E. rhusiopathiae strains induced protection against challenge with three E. rhusiopathiae isolates from dolphins. The duration of the protection varied, depending on the challenging isolate, between 8 and >23 weeks. There was however no positive correlation between the amount of antibodies at the moment of challenge and the observed protection.In conclusion, vaccination trials in mice indicate that commercial serotype 2 swine Erysipelothrix vaccines induce protection against erysipelas caused by dolphin pathogenic isolates.